Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to Hold Rating

Immunic (NASDAQ:IMUX) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. D. Boral Capital reiterated a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Stock Performance

Shares of NASDAQ:IMUX traded up $0.06 during trading on Wednesday, hitting $1.16. The company’s stock had a trading volume of 482,325 shares, compared to its average volume of 943,320. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The business has a 50 day moving average price of $1.05 and a two-hundred day moving average price of $1.23. The company has a market capitalization of $104.49 million, a PE ratio of -0.94 and a beta of 1.89.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IMUX. Invesco Ltd. purchased a new position in Immunic in the 4th quarter valued at $37,000. Virtu Financial LLC acquired a new stake in shares of Immunic in the 3rd quarter worth $50,000. HB Wealth Management LLC purchased a new stake in shares of Immunic in the fourth quarter valued at about $81,000. Barclays PLC acquired a new position in shares of Immunic during the fourth quarter worth about $84,000. Finally, Jane Street Group LLC raised its holdings in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.